Table 1.

Effects of doxorubicin with/without sitagliptin pretreatment on ECG parameters

Groups	HR (bpm)	R-R interval (ms)	QRS duration (ms)	QTc interval (ms)	R wave voltage (mv)
Control	363.3 ± 11.09	145 ± 8.5	47.5 ± 3.2	145 ± 8.6	0.69 ± 0.033
DOX	273 ± 6.03***	267.5 ± 6.3***	88.8 ± 8.4***	231.9 ± 9.3***	0.43 ± 0.017***
Sitagliptin (10 mg/kg) + DOX	322.9 ± 9.9*##	235.6 ± 6.1***##	63.1 ± 6.1#	170.8 ± 3.5###	0.5 ± 0.023***
Sitagliptin (20 mg/kg) + DOX	350 ± 10.6###	190.7 ± 3.5***###	56.9 ± 5.5##	151.8 ± 9.7###	0.62 ± 0.016###

DOX: doxorubicin.

Note: Data are the mean ± SEM (n = 8).

^*P < 0.05, ***P < 0.001 significantly different as compared to the control.

^#P < 0.05, ^##P < 0.01, ^###P < 0.001 significantly different as compared to the DOX group (ANOVA followed by Tukey-Kramer multiple comparison as a post-hoc test).